Allergan, Shire Battle In Dry Eye As Generics Advance

Market Snapshot: Shire is pushing Xiidra hard to take market share away from Allergan's well established Restasis, but the pending arrival of a generic Restasis throws a curveball into the whole category.

Jousting
As Restasis does battle with Xiidra, generic and pipeline challengers wait in the wings • Source: Shutterstock

Dry eye disease was a relatively quiet therapeutic category with Allergan PLC's Restasis (cyclosporine ophthalmic emulsion) the only approved drug in the US and Europe for many years, but now the area is poised for activity in the aftermath of the 2016 US approval of a second drug, Shire PLC's Xiidra (lifitegrast). Allergan and Shire own the roughly $1.7bn market niche, for now, but that's about to change as new drugs and generics reach the field.

[Sidebar#SC100033]

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Sensory

More from Therapeutic Category